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Introduction: Aberrant expression of the embryonic stem cell marker Sox2 has been reported in breast cancer (BC).
We previously identified two phenotypically distinct BC cell subsets separated based on their differential response
to a Sox2 transcription activity reporter, namely the reporter-unresponsive (RU) and the more tumorigenic
reporter-responsive (RR) cells. We hypothesized that Sox2, as a transcription factor, contributes to their phenotypic
differences by mediating differential gene expression in these two cell subsets.
Methods: We used chromatin immunoprecipitation and a human genome-wide promoter microarray (ChIP-chip) to
determine the promoter occupancies of Sox2 in the MCF7 RU and RR breast cancer cell populations. We validated
our findings with conventional chromatin immunoprecipitation, quantitative reverse transcription polymerase chain
reaction (qPCR), and western blotting using cell lines, and also performed qPCR using patient RU and RR samples.
Results: We found a largely mutually exclusive profile of gene promoters bound by Sox2 between RU and RR cells
derived from MCF7 (1830 and 456 genes, respectively, with only 62 overlapping genes). Sox2 was bound to stem
cell- and cancer-associated genes in RR cells. Using quantitative RT-PCR, we confirmed that 15 such genes, including
PROM1 (CD133), BMI1, GPR49 (LGR5), and MUC15, were expressed significantly higher in RR cells. Using siRNA
knockdown or enforced expression of Sox2, we found that Sox2 directly contributes to the higher expression of these
genes in RR cells. Mucin-15, a novel Sox2 downstream target in BC, contributes to the mammosphere formation of BC
cells. Parallel findings were observed in the RU and RR cells derived from patient samples.
Conclusions: In conclusion, our data supports the model that the Sox2 induces differential gene expression in the two
distinct cell subsets in BC, and contributes to their phenotypic differences.Introduction
Sex-determining region Y (SRY)-box binding protein-2
(Sox2) is a transcription factor essential to the mainten-
ance of the pluripotent stem cell state in embryonic stem
cells (ESCs) and induced pluripotent stem cells [1-3]. In
human ESCs, Sox2 governs their pluripotency by binding
to the promoters of its target genes and transcriptionally* Correspondence: rlai@ualberta.ca
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unless otherwise stated.regulating their expressions both positively and negatively
[2]. A previous study of Sox2 promoter occupancy in
human ESCs using chromatin immunoprecipitation pro-
moter microarray chip analysis (ChIP-chip) has revealed
target genes positively regulated by Sox2 (including SOX2,
OCT4, NANOG and MYC) [2]. In normal adult tissues,
Sox2 is largely restricted to somatic stem cells; specifically,
Sox2 expression has been detected in the stem/progenitor
cells of the brain, stomach, colon, and anus [4]. In normal
mammary glands, Sox2 is largely restricted to the stem
cell populations [5-8].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rantly expressed in cancer cells, including those of the
lungs, brain, ovaries, bone, colon, skin, and breasts [8-15].
In many of these studies, Sox2 was found in the cancer
stem cell population [7,12,16-22], supporting the hy-
pothesis that cancer stemness is related to the aberrant
expression of ESC proteins. It has been demonstrated that
Sox2 promotes key tumorigenic properties in cancer
cells, including enhanced proliferation, invasion, migra-
tion, colony formation, non-adherent stem cell-associated
sphere formations in vitro, and tumorigenicity in vivo
[8,12,19-24]. Further, Sox2 has been shown to correlate
with a worse prognosis in cancer patients, including
those with breast cancer (BC) [7,15,25-28]. Up to 30%
of BC, including all four major molecular subtypes,
have been reported to express Sox2 [7,8]. In a rela-
tively small number of in vitro studies, Sox2 has been
directly implicated in promoting cell proliferation,
mammosphere formation, invasion and tumorigenesis
in BC [7,8,29].
We recently identified and characterized two dis-
tinct cell subsets of BC, separated based on their differ-
ential responsiveness to a Sox2 transcription activity
reporter [18]. Using two estrogen receptor-positive (ER+)
cell lines, MCF7 and ZR751, we found that the vast
majority of these cells, despite robust levels of Sox2, were
reporter unresponsive (labeled as RU cells), while a rela-
tively small cell subset were reporter responsive (labeled
as RR cells) [18]. Importantly, RU and RR cells are
phenotypically distinct, with RR cells showing a higher
expression of the stem cell marker CD49f and exhi-
biting a higher tumorigenic potential [18]. In view of
the fact that Sox2 is a transcription factor, we hypothe-
sized that Sox2 mediates differential gene expressions in
RU and RR cells, thereby contributing to their pheno-
typic differences. To test this hypothesis, we analyzed
and compared the global promoter occupancy of Sox2
in RU and RR cells using ChIP-chip. As detailed below,
we found that the Sox2 gene promoter occupancy
between RU and RR cells are mutually exclusive. Import-
antly, we identified a number of stem cell- or cancer-
associated genes that were more highly expressed in RR
cells.
Methods
Cell lines and materials
MCF7 and ZR751 parental cells were purchased from
American Type Culture Collection (ATCC, Rockville, MD,
USA). MCF7 and ZR751 parental cells, unsorted cells, RU
(previously referred to as GFP Neg), and RR (previously
referred to as GFP Pos) cells were cultured and derived as
previously described [18]. Triptolide was purchased from
Sigma-Aldrich (T3652, Sigma-Aldrich Canada, Oakville,
ON, Canada).Sox2 transcription activity reporter
The commercially available Sox2 transcription activity re-
porter is driven by a minimal CMV promoter followed by
three tandem repeats of the Sox2 regulatory region 2
(SRR2), a sequence containing a Sox2 consensus sequence
demonstrated to be bound by Sox2 in mouse and human
embryonic stem cells [30].
ChIP (chromatin immunoprecipitation)-chip and ChIP-PCR
ChIP-chip was performed based on a previously de-
scribed ChIP-PCR protocol [18]. The starting material
was scaled up four times, such that starting materials
were four 15-cm plates of both MCF7 RU and RR cells,
and four identical immunoprecipitations were performed
for each condition (MCF7 RU and RR, IgG and Sox2
IPs). The resulting DNA was further purified using the
QIAquick PCR Purification Kit (Qiagen Canada, Toronto,
ON, Canada), lyophilized, and reconstituted in 10 μL of
UltraPure DNase/RNase-free distilled water (Life Tech-
nologies, Burlington, ON, Canada). The DNA was sub-
sequently amplified twice using the Sigma GenomePlex
Complete Whole Genome Amplification Kit (#WGA2,
Sigma-Aldrich Canada) using a published adapted proto-
col [31]. ChIP-PCR was performed as previously described
[18]. ChIP input DNA was run on an agarose gel to check
for microarray optimized DNA fragments of 200 to 1200
bp (Additional file 1: Figure S1A ). DNA samples were
sent in two replicates to Roche Nimblegen ChIP-chip
Microarray Services for quality assessment, and full ser-
vice ChIP-chip microarray service and analysis. Briefly,
DNA samples were hybridized to the Roche Nimblegen
Human ChIP-chip 3x720K RefSeq Promoter array, with
promoter tiling ranging from -3,200 to +800 relative to
the transcription start site. The ChIP-chip microarray data
have been submitted to the public repository Gene Ex-
pression Omnibus [GEO: GSE61703]. Primers for ChIP-
PCR were designed to flank the promoter peaks identified
by ChIP-chip analysis for each gene.
RNA extraction, cDNA synthesis, quantitative reverse
transcription PCR (qPCR)
Total RNA extraction was performed with the Qiagen
RNeasy Kit (Qiagen Canada) according to the manufac-
turer’s protocol: 1 μg of RNA was reverse transcribed using
Oligo dT and Superscript II (Life Technologies) according
to the manufacturer’s protocol. 1 μL of the resulting cDNA
mixture was added to the Platinum SYBR Green qPCR
SuperMix-UDG with Rox (Life Technologies) and amplified
with target gene-specific primers. Please see Additional
file 2: Table S1 for list of PrimerBank primer sequences
[32,33]. All genes of interest are normalized to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) transcript expression
levels except for the Triptolide experiments where 18S rRNA
was used as the housekeeping gene for its superior stability.
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Sox2 siRNAs (SMARTpool: ON-TARGETplus SOX2
siRNA, Dharmacon, Thermo Scientific, Waltham, MA,
USA) or scrambled (Scr) siRNAs (ON-TARGETplus Non-
targeting Pool, #477C20, Dharmacon, ThermoScientific)
at 40 pmol per rxn (20 nM final concentration) and 5 μL
of Lipofectamine RNAiMAX (Life Technologies) were
added to 0.5 mL of OptiMEM media (Life Technologies)
and reverse transfected to 800,000 cells in normal cul-
ture medium in a 6-well plate format. Cells were incu-
bated with siRNAs for 72 hours before harvesting. Muc15
siRNA (#SI04331166, Qiagen Canada, and SMARTpool:
ON-TARGETplus MUC15 siRNA, Dharmacon) was
transfected in the same manner at 80 pmol and 200
pmol per rxn respectively (40 nM and 100 nM final
concentration).
Western blotting
Western blot analyses were performed as previously de-
scribed [34]. All antibodies were diluted in 5% BSA in
TBST: Sox2 (1:500, #2683-1, Epitomics, Burlingame, CA,
USA), FlagM2 (1:1000, #F1804, Sigma-Aldrich), Muc15
(1:500, #ab98045, Abcam, Cambridge, UK), and vinculin
(1:1000, #4650, Cell Signaling Technologies, Danvers,
MA, USA). Vinculin was used as loading control for all
western blots.
Plasmid transfections
We transfected 3 μg of pcDNA-Flag-EV or pcDNA-Flag-
Sox2 with 5 μL of Lipofectamine 2000 (Life Technologies)
in 0.5 mL of OptiMEM media (Life Technologies) to 1.2
million MCF7 cells seeded the day before. Cells were incu-
bated for 72 hours before harvesting.
Mammosphere assay
Mammospheres were generated as previously described
[18]. Mammospheres were collected by centrifugation at
300 × g for 5 minutes and trypsinized before subjecting
to trypan blue exclusion assay of mammosphere-derived
cells.
Primary patient breast tumor cells isolation, lentiviral
infections, fluorescence-activated cell sorting (FACS)
purification
Patient material and clinical information were collected
with full written consent from the patients and with ap-
proval by the University of Alberta Human Research
Ethics Board, approved project ID Pro00044942. Fresh
breast tumors were collected in cold 100% FBS and har-
vested within hours. We isolated breast tumor cells from
fresh breast tumor tissues with no exposure to radi-
ation therapy or chemotherapy. We harvested purified
primary BC cells first by mechanical dissociation and
then by using the Cancer Cell Isolation Kit (PanomicsSolutions, Affymetrix, Santa Clara, CA, USA) as per manu-
facturer’s protocol. Cells were cultured in 10% RPMI
medium for 48 hours before virus infection. We generated
a new dual green fluorescent protein (GFP)/red fluorescent
protein (RFP) lentiviral Sox2 reporter by replacing the
puromycin resistance gene in the Sox2 reporter with the
red fluorescent protein (RFP) gene. Isolated tumor cells
were infected with our modified lentiviral Sox2 GFP-RFP
dual-color reporter, SRR2-mCMV-GFP-EF1-RFP, twice 24
hours apart. RFP+ cells were gated to include only suc-
cessfully infected primary breast tumor cells in subsequent
analyses and experiments. Using flow cytometry, we ana-
lyzed and collected RFP+/GFP- (RU) and RFP+/GFP+
(RR) cells.
Statistical analyses
The paired Student’s t-test was used for statistical ana-
lysis of experiments throughout: *P <0.05; **P <0.01.
Results
The Sox2-bound gene promoter regions are largely
mutually exclusive between RU and RR cells
Using ChIP-chip, we queried the global promoter occu-
pancy profile of Sox2 in the two phenotypically distinct
cell subsets, namely RU and RR cells. Using a stringent
threshold (a promoter array peak signal >2.0, compared to
the input DNA signal) and a false discovery rate of <0.05,
we found that Sox2 was bound to the promoter regions of
1,830 genes in RU cells and 456 genes in RR cells, with an
overlap of only 62 genes between the two cell subsets (il-
lustrated in Figure 1A). The complete RU and RR gene
lists can be found in Additional file 3: Table S2. ChIP-chip
gene promoter analyses are detailed in Additional file 1
(Supplementary materials and methods).
To understand the possible biological effects exerted by
Sox2 in BC cells, we annotated the functions of the identi-
fied genes using the Protein Analysis THrough Evolution-
ary Relationships (PANTHER) Protein Class classification
system software [35]. As shown in Figure 1B, the biological
functions associated with the identified genes are largely
similar between the RU and RR cells, with the functions
falling most frequently into the categories of hydrolases,
nucleic acid binding, and receptors.
The RR gene list comprise markers associated with cancer
stem cells
As we have previously shown that RR cells exhibit more
tumorigenic and stem-like properties than RU cells [18]
we hypothesized that the ChIP-chip gene list derived from
RR cells will contain genes that are known to be associ-
ated with cancer stem cells. To test this hypothesis, we
searched our RR gene lists for reported cancer stem cell
markers, based on those described in two recent publica-
tions [36,37]. We found that Sox2 was bound to the gene
Figure 1 (See legend on next page.)
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Figure 1 Sex-determining region Y (SRY)-box binding protein-2 (Sox2) occupies distinct promoter regions in reporter unresponsive
(RU) and reporter responsive (RR) breast cancer cells. (A) Venn diagram of MCF7 RU and RR cells Sox2 chromatin immunoprecipitation promoter
microarray chip analysis (ChIP-chip) study summarizing gene promoters bound by Sox2. (B) Functional annotation of MCF7 RU and RR putative Sox2
target genes with >2.0 peak score signal (compared to input DNA) using Protein Analysis THrough Evolutionary Relationships (PANTHER) Protein Class
system. (C) MCF7 RU and RR ChIP DNA agarose gel results of DNA sequences immunoprecipitated by normal rabbit IgG or a rabbit anti-human Sox2
antibody amplified by GPR49 and MUC15 promoter specific primers. MCF7 RU and RR input represent the DNA isolated from chromatin before
immunoprecipitation to show equal input amounts. Quantitative-PCR analyses of ChIP DNA derived from the IgG and Sox2 ChIP of MCF7 RU and
RR cells using promoter-specific primers. Sox2 ChIP-qPCR signal was normalized to IgG signal as well as the respective RU and RR input signal.
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tumors, including CD133 (PROM1), Lgr5 (GPR49), and
Bmi-1 (BMI1). Importantly, these three genes were not on
the RU gene list.
When we examined the remaining 453 genes identi-
fied in RR cells, we identified 12 additional genes that
have been previously implicated in cancer initiation
and/or progression (Table 1). These genes include FZD4
(the Wnt pathway) [38,39], PLAU (encoding metastasis-
promoting protein urokinase plasminogen activator) [40]
and ELF5 (a normal mammary stem/progenitor cell gene)
[41]. None of these 12 genes were found in the RU gene
list and the majority of these genes (8 of 15) had a very
high microarray signal >2.5. Interestingly, ANTXR1, also
found in our RR gene list, which encodes anthrax toxin
receptor-1, has just been recently reported as a stem cell
gene important to the tumorigenesis of BC [42,43]. Again,
this gene was not found in the RU gene list.Table 1 Sox2 interacts with the promoters of stem cell





PLXNA2 Plexin A2 3.19
FZD4 Frizzled homolog 4 (Drosophila) 3.16
MUC15 Mucin 15, cell surface associated 3.04
PLAU Plasminogen activator, urokinase 2.89
ELF5* E74-like factor 5 (ets domain
transcription factor)
2.88
VCAM1 Vascular cell adhesion molecule 1 2.68
DACH2 Dachshund homolog 2 (Drosophila) 2.55
GPR49* Leucine-rich repeat-containing
G protein-coupled receptor 5
2.55
FYB FYN binding protein 2.43
COL4A5 Collagen, type IV, alpha 5 2.40
MYH9 Myosin, heavy chain 9, non-muscle 2.39
PROM1 (CD133)* Prominin 1 2.20
ESR2 Estrogen receptor 2 (ER beta) 2.19
PLAG1 Pleiomorphic adenoma gene 1 2.19
BMI1* BMI1 polycomb ring finger oncogene 2.17
List of RR ChIP-chip putative Sox2 target genes. Top-ranked 15 stem cell and/
or cancer-associated genes of interest with >2.0 peak score derived from the
MCF7 reporter responsive cells and their final adjusted microarray peak scores
are summarized. The asterisks denote established stem cell markers.Validation of the ChIP-chip data using ChIP-PCR
We then aimed to validate the observation that the gene
promoters bound by Sox2 in RU and RR cells are largely
non-overlapping. To do so, we employed ChIP-PCR and
used two genes from the RR gene list that show relatively
high microarray signals and robust mRNA expression in
BC cells, namely GPR49 and MUC15 [44,45]. The ChIP-
PCR primers for these two genes were designed to flank
the exact promoter locations specified by the ChIP-chip
microarray probes. As shown in Figure 1C, in RR cells, we
detected more robust Sox2 binding at both the GPR49
and MUC15 gene promoters than in the RU cells that
showed barely detectable to no binding. These ChIP-PCR
results support the validity of the ChIP-chip findings. To
further validate our ChIP-PCR findings, we also pursued
ChIP-qPCR analyses of six gene promoters of interest
with high peak scores from the RR gene list, and validated
that Sox2 was significantly more frequently bound to
these promoters in the RR cells when compared to the RU
cells (Figure 1C).
To further test if Sox2 binds to different sets of gene
promoters between RU and RR cells, we performed ChIP-
PCR to detect the binding of Sox2 to CCND1 (Cyclin D1)
promoter, a direct Sox2 gene target previously shown by
us and others [8,18]. We found the interaction between
Sox2 and the CCND1 gene promoter, but only in RR (data
not shown, previously reported by us [18]. We also vali-
dated our ChIP DNA by looking at several Sox2 target
genes found in human ESCs previously described in the
literature, including BCL2 and CDH1 [46] As shown in
Additional file 1: Figure S1B, we found that Sox2 showed
significantly greater binding at the promoters of BCL2
and CDH1 in RR cells than in RU cells. Of note, CCDN1,
BCL2, and CDH1 were not found in our ChIP-chip gene
list, likely due to our very stringent analysis criteria, which
were used to identify only the most frequently bound
DNA sequences in BC cells.
RR cells express elevated levels of target genes compared
to RU cells
We next asked if the differential Sox2 gene promoter oc-
cupancy between RU and RR cells correlates to significant
differences in gene expression between these two cell sub-
sets. Using qRT-PCR, we measured and compared the ex-
pression levels of the 15 genes of interest described in
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nificantly higher (2- to 5-fold) gene transcript levels of 14
out of these 15 genes (Figure 2). These results support our
hypothesis that Sox2 mediates differential gene expression
between RU and RR cells.
Overexpression of Sox2 up-regulates target genes in RR
cells but not RU cells
To demonstrate the direct role of Sox2 in contributing to
the differential gene expression between RU and RR, we
examined if enforced expression of Sox2 in MCF7 cells
results in significant alterations of their expressions. For
the purpose of this study, we chose 7 of the 15 genes, based
on their relatively high ChIP-chip peak scores, includ-
ing PLXNA2, FZD4, MUC15, PLAU, ELF5, GPR49 and
PROM1. As shown in Figure 3A, with transient trans-
fection of Sox2 into RR cells, all seven genes examined
showed a significant increase in their transcript levels in
RR cells (3- to 7-fold); conversely, RU cells showed no sig-
nificant alterations of any of these seven genes.
SiRNA knockdown of Sox2 downregulates target genes
Next, we examined if siRNA knockdown of Sox2 also
can modulate the expression of the seven target genes
tested. As shown in Figure 3B, the efficiency of the
knockdown was demonstrated by western blotting and
quantitative RT-PCR. We found that Sox2 siRNAs sig-
nificantly downregulated these target genes in RR cells.
Surprisingly, the same treatment also significantly down-
regulated the expression of these seven genes in RU
cells. Similar findings were also observed in MCF7 par-
ental cells, which predominantly comprise RU cells
(Additional file 1: Figure S2). As Sox2 did not induce
an increase in the expression of Sox2 target genes in RU
cells (Figure 3A), we hypothesized that the downregulationFigure 2 Reporter responsive (RR) cells exhibit higher expression of t
chromatin immunoprecipitation promoter microarray chip analysis (ChIP-chof Sox2 target genes in RU cells induced by Sox2 siRNA
was mediated in a transcription-independent manner. If
this is the case, the gene transcripts in RR cells are ex-
pected to be more sensitive to transcription inhibition
than those in RU cells. In keeping with this concept, the
addition of the transcription inhibitor, Triptolide, sig-
nificantly decreased the transcript level of PROM1
(CD133) in RR cells but paradoxically increased that
in RU cells (Figure 3C).
Mucin-15, a novel Sox2 target, contributes to
mammosphere formation
To further support the concept that Sox2 contributes to
tumorigenesis and stemness in BC by upregulating these
stem cell- or cancer cell-associated genes, we examined
the oncogenic effects of Mucin-15 (Muc15), which has not
been previously shown to be a Sox2 downstream target.
While Muc15 has been shown to play a key role in increas-
ing invasiveness and tumorigenic capacity in colon cancer
[47], it has not been linked to BC. As shown in Figures 2
and 4A, Muc15 was more highly expressed at the mRNA
and protein levels in RR cells, as compared to RU cells.
Furthermore, as shown above, overexpression or knock-
down of Sox2 significantly modulated the expression of
Muc15. As shown in Figure 4B, knockdown of Muc15
using siRNA significantly decreased the number of mam-
mospheres formed from MCF7 unsorted cells, which
comprise natural proportions of RU and RR subsets. Fur-
thermore, using trypan blue exclusion assay, we found
that siRNA knockdown of Muc15 significantly reduced
the number of viable cells derived from the mammo-
spheres (Figure 4B). The same experiment was repeated
using four pooled unique siRNA sequences and we ob-
served the same results, with Muc15 knockdown verified
(Additional file 1: Figure S3).arget genes. Quantitative-PCR mRNA transcript analysis of top 15 RR
ip) genes in MCF7. RU, reporter unresponsive cells.
Figure 3 Sex-determining region Y (SRY)-box binding protein-2 (Sox2) can upregulate target gene transcripts in reporter responsive
(RR) cells only and not reporter unresponsive (RU) cells. (A) MCF7 RU and RR cells were transfected with 3 μg of pcDNA3-Flag-Empty vector
(EV), or pcDNA3-Flag-Sox2 (Sox2) and harvested for mRNA after 72 hours. Quantitative (q)-PCR analyses were performed using primers designed
against MCF7 RR chromatin immunoprecipitation promoter microarray chip analysis (ChIP-chip) targets. Accompanying Sox2 qPCR analysis and
Flag western blot shows transfection efficiency. (B) Western blot showing Sox2 knockdown efficiency in MCF7 RU and RR cells after 72-hour
20-nM scrambled or Sox2 siRNA treatment. q-PCR mRNA transcript analysis of MCF7 RU and RR cells after 72-hour 20-nM scrambled or Sox2 siRNA
knockdown examining RR ChIP-chip genes in MCF7 RU and RR. (C) q-PCR analysis of MCF7 RU and RR cell PROM1 (CD133) transcripts after 16-hour
treatments with dimethyl sulfoxide vehicle control or 10, 20, 30, or 40 nM Triptolide.
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exhibit elevated tumorigenic properties and expression of
target genes
Lastly, we examined if BC cells derived from patient sam-
ples displayed similar findings to the MCF7 cells. Due tothe relatively small number of tumor cells available, and
the relatively low proportions of RR cells, we modified our
Sox2 reporter such that it carried two signals, with the ex-
pression of RFP indicating successful infection with the
viral vector, and the GFP signal indicating Sox2 reporter
Figure 4 Mammosphere formation is dependent on novel sex-determining region Y (SRY)-box binding protein-2 (Sox2) target Muc15.
(A) Western blot analysis of Muc15 in MCF7 reporter unrepsonisve (RU) and reporter responsive (RR) cells. (B) MCF7 unsorted cells were treated
with 40 nM of Muc15 siRNA for 72 hours before seeding into mammosphere culture. Mammospheres were counted on day 7, and subsequently
trypsinized and counted after trypan blue incubation. Accompanying western blot shows Muc15 knockdown efficiency.
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pressing RFP but not GFP were regarded as RU cells,
whereas those lacking both RFP and GFP were excluded
from the analysis. Results from 19 primary BC tumors are
summarized in Table 2. All 19 samples contained a detect-
able subset of RR cells, and the size of this population
ranged from 0.3% to 23.8%. Interestingly, estrogen
receptor-negative tumors (n = 3) had a significantly lower
proportion of RR cells (p = 0.001). Functional studies were
performed in eight samples in total. As shown in Figure 5A,
RR cells were more efficient in forming colonies on
methylcellulose agar in four out of four patient cells sam-
pled. Importantly, as we gated our cells using RFP and
GFP expression, we demonstrate that the RFP+ GFP- cells
were healthy in culture (Additional file 1: Figure S4A-B).
Under a fluorescence microscope, the cells were con-
firmed to be RFP+ (data not shown). As shown in
Additional file 1: Figure S4B-C, RU and RR cells derived
from patient samples had a similar Sox2 protein expression
level in the nuclei, suggesting that the differences observed
are not simply due to a lack of Sox2 protein or Sox2 nu-
clear localization in RU cells. Using fresh primary patient
samples, we went on to test if RU and RR cells also differin the expression of Sox2 downstream targets. Due to the
relatively small number of primary samples available for
testing, we chose three genes, including PROM1 (CD133),
GPR49 (LGR5), and MUC15, based on the fact that the
expression of these genes were amongst the most respon-
sive to modulation of Sox2 (Figure 3A and B). As shown
in Figure 5B, in a total of seven fresh primary patient sam-
ples, we detected higher expression of these three genes in
patient RR cells as compared to their RU counterparts, al-
though statistical analysis was not possible for all due to
limitations in patient materials. Further, some patient
samples did not contain enough RNA for analysis for all
genes. Nevertheless, the overall findings from patient sam-
ples appear to mirror those in MCF7 cells.
Discussion
We recently identified two Sox2-expressing, phenotypic-
ally distinct cell subsets in BC cells, separated based on
their differential response to a Sox2 transcription activity
reporter, with RR cells showing higher tumorigenicity
and more stem-like features relative to RU cells [18]. In
the same study, we also found that these phenotypic dif-
ferences are dependent on Sox2, as siRNA knockdown
Table 2 RU and RR cell populations are detectable in













1 64.2% 13.9% 2+ +
2 48.7% 11.0% 2+ +
3 63.1% 16.1% 1+ +
4 57.8% 0.6% N/A -
5 43.0% 10.8% N/A +
6 49.7% 0.3% 3+ -
7 81.3% 12.5% N/A +
8 77.3% 21.4% 1+ +
9 36.3% 0.4% N/A -
10 61.0% 11.5% N/A +
11 - * 5.7% 0 +
12 - * 5.8% 3+ +
13 - * 17.0% N/A +
14 - * 21.6% N/A +
15 - * 23.8% 3+ +
16 - * 19.6% 2+ +
17 -* 5.4% N/A N/A
18 -* 10.5% N/A N/A
19 -* 5.8% N/A N/A
Flow cytometry analyses of red fluorescent protein (RFP) and green fluorescent
protein (GFP) in mCMV-GFP-EF1-Puro infected primary breast tumor cells to set
the gate thresholds and the SRR2-mCMV-GFP-EF1-RFP infected primary breast
tumor cells showing % RFP+ cells (lentivirus infection efficiency) and % RFP+ GFP+
cells (% of patient reporter responsive (RR) cells). Table summarizes data from 19
primary breast tumor samples. The asterisks denote samples where the primary
breast tumor cells % RFP+ could not be accurately assessed due to technical issues
but is estimated to be approximately 60%. IHC denotes immunohistochemistry;
N/A, not analyzed.
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[18]. Because Sox2 is a transcription factor, we hypothe-
sized that Sox2 contributes to the phenotypic differences
between RU and RR cells by mediating differential gene ex-
pression. To test this hypothesis, we compared the Sox2
gene occupancy in RU cells with that of RR cells. Import-
antly, we found a largely mutually exclusive Sox2 promoter
occupancy between these two cell subsets. Furthermore,
there were a number of cancer- or stem-cell associated
genes that are only found in the RR gene lists. Experiments
using enforced expression or siRNA knockdown of Sox2
support the direct role of Sox2 in regulating these genes.
The biological significance of our findings is supported by
our results generated from the use of patient samples.
Taken together, we believe that the overall findings lend
support to our hypothesis.
Although aberrant Sox2 expression is well-documented
in cancer, its mechanism of action in the regulation of
downstream targets is incompletely understood. Currently,
with the exception of CCND1 (encoding Cyclin D1) [8], noother gene has been identified as a direct downstream
target of Sox2 in BC. Nevertheless, a few Sox2 down-
stream gene targets have been reported in other cancer
types, including PROM1 (encoding CD133) in human
lung cancer cells [48] and ITGA6 (encoding CD49f) in hu-
man mesenchymal stem cells [49]. Regarding the func-
tional importance of Sox2 in cancer, an exciting finding
from our ChIP-chip study is that Sox2 was bound to the
promoters of many cancer- and stem cell-associated genes
in RR cells. This finding correlates well with the prevail-
ing concept that the expression of embryonic stem cell
markers in cancer cells results in stem-like features, which
are often associated with an aggressive clinical course
and treatment resistance [36,50]. We believe that our
finding of Sox2 regulating an array of cancer- and stem
cell-associated genes provides a mechanistic explan-
ation as to how Sox2 enhances stemness and tumorigenesis
in cancer cell subsets. The importance of stem cell markers
in identifying cancer stem cells, including Frizzled-4, Lgr5,
and CD133 have previously been demonstrated [39,51,52],
and here our data suggest that their expressions may
be dependent on common precursor protein Sox2. Further-
more, we have demonstrated that CD133 and Lgr5 mRNA
transcripts were also upregulated in primary tumor-derived
RR cells from patients.
Importantly, it should be noted that the identification of
our list of 15 novel Sox2 targets were hand-picked by us
using a manual search approach. As we were most inter-
ested in better understanding how Sox2 contributes to BC
and/or BC stem cell biology, we chose genes with pub-
lished roles in that context. As a result, we have discov-
ered that Sox2 does regulate an intriguing list of genes in
the RR cells, but this does not exclude the possibility that
other important cancer and/or stem cell genes exist in our
ChIP-chip lists. Additionally, as the ChIP-chip assay is
limited by the detection of hybridization of our Sox2-
bound DNA samples to the microarray, our list certainly
does not exhaust all the possible promoter interactions of
Sox2 in BC cells. Importantly, we have done motif ana-
lyses on the ChIP-chip data, and have confirmed that
Sox2 motifs previously published by others are enriched
in our Sox2 ChIP DNA from both subsets [30].
We hypothesize that Sox2 in RU and RR cells are bio-
chemically distinct, allowing for differential transcription
activation ability at unique promoter regions. The RU cells
exhibit no transcription activity as reported by our Sox2
reporter, and here we have shown that Sox2 overexpres-
sion did not transactivate the RR ChIP-chip promoters.
Moreover, we have shown by ChIP-chip and conventional
ChIP-PCR that Sox2 does not occupy the same promoters
in RU and RR cells. These results suggest that Sox2 does
not interact with these promoters in RU cells the same
way as in RR cells. Conversely, Sox2 in RU cells binds to
its own large cohort of gene promoters. This suggests
Figure 5 Reporter responsive (RR) cells derived from primary patient breast tumors exhibit enhanced tumorigenic properties and
elevated expression of target genes. (A) Representative anchorage-independent methylcellulose colony formation assay numerical and pictorial
results from patients 11, 17, 18, and 19 reporter unresponsive (RU) and reporter responsive (RR) cell populations. (B). Quantitative-PCR PROM1, MUC15,
and GPR49 mRNA transcript analysis of fluorescence-activated cell sorting-purified lentiviral Sox2 transcription activity reported-infected primary patient
breast tumor RU and RR cells from patients 13 to 19.
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promoters: 1) Sox2 could be suppressing gene expression
of these genes as we have recently reported [53]; 2) Sox2
is transcriptionally active in RU cell gene promoters but
did not transactivate luciferase or GFP expression fromFigure 6 Schematic diagram of sex-determining region Y (SRY)-box b
in breast cancer cells. Our working model depicts that the Sox2 in report
(RU) cells and confers high transcription activity in that subset perhaps par
nucleus. ChIP, chromatin immunoprecipitation.the reporter due to discrepancies between the reporter
and gene promoters in Sox2 consensus binding sequences
and/or adjacent sequences that can recruit other co-
factors; 3) Sox2 occupancy at these promoters serves as a
positive or negative facilitator to other transcriptional co-inding protein-2 (Sox2) transcription activity heterogeneity model
er responsive (RR) cells is distinct from that of reporter unresponsive
tially through differential interactions with promoter DNA in the
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functional at these promoter regions due to an absent co-
factor or post-translational modification that is present in
RR cells.
While we found that Sox2 is directly involved in regu-
lating the expression of its target genes in RR cells, the
finding that siRNA knockdown of Sox2 decreased gene
transcript expression in RU cells is a rather unexpected
finding. From our previous studies, we found that Sox2
exists in the cytoplasm [18], and it can potentially carry
out functions related to post-transcriptional modifica-
tions and/or translational modulations. One possible ex-
planation is that Sox2 regulates the expression of these
genes by non-transcriptional mechanisms. It is possible
that Sox2 can prolong the integrity and half-life of
specific gene transcripts, or it functions as a translation
factor. To examine the contributions of transcriptional
and non-transcriptional mechanisms in RU and RR cells,
we used transcription inhibitor Triptolide. In RR cells, we
found that Sox2 target PROM1 transcripts were sensitive
to the treatment and the mRNA levels decreased with in-
creasing concentrations, supporting the hypothesis that
Sox2 is transcriptionally activating PROM1. In RU cells,
we did not observe decreased PROM1 transcript levels
with transcription inhibitor treatment, suggesting that
Sox2 in RU cells may have a distinct regulatory mechan-
ism for Sox2 target PROM1.
We have focused on Muc15 in our studies as it is a new
putative onco-protein, consistently highly expressed in RR
cells, and responsive to Sox2 regulation. In particular,
Muc15 is of interest to us as it is relatively unknown in the
cancer biology of any tissue. Muc15 is a highly glycosylated
extracellular mucin protein previously reported to be
expressed in normal epithelial cells, including the breast,
but elevated in tumor cell populations [44,47,54-56]. In
this report, we are the first to identify very high Muc15 ex-
pression in BC cells. Importantly, we detected increased
Muc15 mRNA transcript and protein levels in RR cells
compared to RU cells in cell lines and primary patient
samples. Muc15 was previously demonstrated to promote
oncogenesis in colon cancer cells in vitro and in vivo [47].
Thus, our ChIP-chip study is a good resource for novel
putative therapeutic BC targets.
We showed that the patient RU and RR cells have distinct
phenotypes as demonstrated in an anchorage-independent
methylcellulose colony formation assay and underlying
biology as determined by qPCR. Importantly, we have
confirmed that RU cells from patients, although reporter
unresponsive, do express nuclear Sox2 as detected by im-
munohistochemistry techniques. We have also uncovered
potential mechanisms underlying the more tumorigenic
RR cells as the patient RR cells exhibited higher expres-
sion levels of Sox2 target genes, PROM1, GPR49, and
MUC15 transcripts. Thus, the response of BC cells to theSox2 transcription activity reporter has distinguished pri-
mary patient and cultured cell lines cancer-cell subpopula-
tions with distinct phenotypic and molecular features.
Conclusions
Taken together, we have shown that Sox2 behaves het-
erogeneously in breast tumor cell populations. Sox2 is
strongly bound to a subset of cancer and stem cell gene
promoters and can upregulate the corresponding gene
transcripts in RR cells but not in RU cells. Importantly,
we have identified a novel Sox2 target Muc15 that is im-
portant for mammosphere formation, and is also upreg-
ulated in the tumorigenic RR cells derived from primary
patient breast tissue samples. In summary, we depict in
a schematic diagram where Sox2 in RR cells interacts
with DNA, and/or transcriptionally activates promoters
differently compared to Sox2 in RU cells (Figure 6).
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